StonvexLoading…
StonvexStonvexStonvexCore line items from ICHR's most recent SEC filings (10-K / 10-Q via EDGAR XBRL). Last 4 reporting periods.
| Metric | Q1 2026 2026-03-27 | Annual 2025 2025-12-26 | Q3 2025 2025-09-26 | Q2 2025 2025-06-27 |
|---|---|---|---|---|
Revenue | $256.07M | $947.65M | $724.05M | $484.75M |
Operating Income | $2.08M | $-39.27M | $-25.44M | $-6.01M |
Net Income | $-2.47M | $-52.78M | $-36.82M | $-9.41M |
EPS (Diluted) | $-0.07 | $-1.54 | $-1.08 | $-0.41 |
Total Assets | $972.50M | $942.88M | $966.58M | $985.07M |
Total Liabilities | $304.49M | $278.99M | $290.41M | $290.92M |
Cash & Equivalents | $89.09M | $98.29M | $92.50M | $92.22M |
Free Cash Flow OCF − CapEx | $-9.98M | $-6.28M | $-12.20M | $-14.30M |
Shares Outstanding | 34.74M | 34.43M | 34.38M | 34.24M |